Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: david james who wrote (878)	4/18/2000 8:48:00 PM
From: Bosco	Read Replies (2) \| Respond to of 1298

Hi Dave - no offense, as I consider you my cyberfriend, but we ve discussed this ad nauseum <g> only last week, empirical evidence has suggested nearly all analysts do not count 1 time gain derived from the sale of assets. Or, if you read income statement, which is beyond clueless people like myself <g>, the item people look at is earning from operations. Of course, there are exception to the rules. For example, incubators and asset management companies core business is to harvest their investments. But then, that is their core operations :). You made a good point though. If a company reports the sale of its own stock as earning, it would be a kiss of death <vbg>. In CEGE case, if it does sell ABGX stock, it is a mild positive, if the cash from the sale is deployed meaningfully. Anyway, just my 2c and my last post on this subject best, Bosco